Refine by
Infection Blood Articles & Analysis
22 news found
While there are many types, the most frequent cause of infections in humans is Acinetobacter baumannii. Infections of the blood, urinary tract, and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. It can also colonize or live in a person without causing infections or symptoms, ...
While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are on breathing machines · have devices such as catheters · have open wounds from surgery ...
While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Infections of the blood, urinary tract and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. It can also colonize or live in a person without causing infections or symptoms, ...
Potential advantages of the valve include: For nurses: Greater efficiency through avoiding dislodgements and unscheduled IV restarts Less exposure to sharps injuries and potentially infected blood For hospitals: Reduced potential for infiltrations, phlebitis and healthcare-acquired infections Cost savings due to less need to replace ...
” Potential advantages of Linear Health’s Orchid Safety Release Valve include: For patients: Fewer IV restarts including painful needlesticks Reduced potential for more invasive treatment such as central lines due to loss of peripheral IV integrity For nurses: Greater efficiency through avoiding dislodgements and unscheduled IV restarts Less exposure to sharps injuries ...
Those potential advantages include: For patients: Fewer IV restarts including painful needlesticks Reduced potential for more invasive treatment such as central lines due to loss of peripheral IV integrity For nurses: Greater efficiency through avoiding dislodgements and unscheduled IV restarts Less exposure to sharps injuries and potentially infected ...
JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. ...
This new agreement provides educational resources and programs to MHA members on best practices in blood culture collection and the role of clinically proven solutions, including Steripath, in virtually eliminating blood culture contamination at the source. ...
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, ...
Each year, more than 1.4 million patients with false-positive blood culture results are put at risk for sepsis misdiagnosis which can have serious impacts including unnecessary and prolonged antibiotic therapy, extended hospital stays, increased risk of hospital-acquired infections and increased morbidity and mortality. ...
“Having participated in the development of the rapid ID market with GenMark’s syndromic PCR solution, I know from that our leading customers now need an affordable, high throughput, and easy to use rapid AST, especially for blood infections. Specific’s Reveal is the best-in-class instrument to meet this need, and I am keenly looking forward to ...
These conferences and journals include the Emergency Nurses Association (ENA), Association for Professionals in Infection Control (APIC), Society for Healthcare Epidemiology of America (SHEA), American Journal of Medical Quality, Journal of Hospital Infection, American Journal of Infection Control, and Journal of Emergency Nursing. ...
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. ...
Nucleic Acid Test (NATs) NATs test for actual virus present in the blood. These tests tend to be very expensive and are reserved for recent high-risk exposure or potential exposure and early symptoms of infection. ...
ByFluxergy
While rapid ID instrumentation for blood stream infections is now widely available, clinicians often wait additional 1 to 2 days to receive the AST results required to identify the optimal antibiotic therapy, which the ID result alone does not enable. ...
In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations ...
” The LSI – Cytovale’s IntelliSep test – is an investigational, pathogen-agnostic direct assessment of white blood cell activation, which allows for rapid quantification of host immune response in an acute care setting. It utilizes routine blood draw samples, requiring minimal operator handling, and achieves a ...
” For the new publication, Inflammatix and Stanford scientists applied advanced machine learning to develop a 29-gene classifier (“BVN-1”) that can identify bacterial, viral or no infections across 1,069 blood samples from 18 prior studies of patients diagnosed with acute infections. ...
The new capital will go toward expanding its needle-less blood draw device and to developing new technologies. CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s mission of reducing the costs and risk of infections associated with blood draws. ...
Not surprising as the Vascular Access discipline can easily document its financial value by demonstrating up to millions in cost savings by reducing the number of central line-associated blood stream infections (CLABSIs) and/or complications and waste associated with peripheral intravenous catheters (PIVs). ...